Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
May 17, 2023 09:00 ET
|
Umoja Biopharma, Inc.
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model...
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 03, 2023 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...
Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 10:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
December 14, 2022 07:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with...
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
November 21, 2022 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE and SAN JOSE, Calif. and SHANGHAI, China and NANJING, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated...
Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022 09:00 ET
|
Umoja Biopharma, Inc.
New data shows that CAR T cells engineered in vivo with VivoVec particles mediate durable antitumor activity Potent and durable anti-tumor activity demonstrated with a universal TagCAR targeted...
Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 19, 2022 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board
September 13, 2022 09:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...
Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation, a Novel Approach for the Differentiation and Expansion of Induced Pluripotent Stem Cells to Generate Cytotoxic Innate Lymphocytes
July 28, 2022 16:00 ET
|
Umoja Biopharma, Inc.
New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™) as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACRTM...
Umoja Biopharma Announces Participation in Upcoming Scientific Summits
June 30, 2022 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients...